Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Essilor International /FI Unsponsored ADR(ESLOY US)

Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Essilor International /FI Unsponsored ADR(ESLOY US)

Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
ESLOY US​
Ask AI

Essilor International /FI Unsponsored ADR — Company Profile

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Exchange
UU
CEO
Francesco Milleri
Headquarters
Paris, I0, FR
IPO Date
Jan 30, 2008
Employees
203,791
Website
www.essilorluxottica.com

Key Metrics

Price
$80.84
Market Cap
$74.31B
Revenue (TTM)
$27.37B
Net Income (TTM)
$2.22B
EPS (TTM)
2.42
P/E (TTM)
0.00
P/B (TTM)
1.91
Dividend Yield
2.38%
ROE (TTM)
5.72%
ROA (TTM)
3.48%
Operating Margin
11.80%
Beta
0.86

Dividends

Last Dividend
$2.35
Last Yield
0.02%

Summary

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.

Website
www.essilorluxottica.com
Location
Paris, I0, FR
Phone33 1 49 77 42 16
Employees203,791
CEOFrancesco Milleri
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO DateJan 30, 2008

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(87)

Expand
  • F-6EFEffective registration statement (depository shares)25 Nov 2019
  • F-6 POSPost-effective amendment (depository shares)18 Oct 2018
  • F-6 POSPost-effective amendment (depository shares)9 Oct 2018
  • Form 425Business combination communication17 May 2017
  • Form 425Business combination communication29 Mar 2017
  • Form 425Business combination communication29 Mar 2017
  • Form 425Business combination communication23 Mar 2017
  • Form 425Business combination communication21 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication24 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • SC 13DCOSTA INC18 Nov 2013
  • Form 3ESSILOR INTERNATIONAL /FI18 Nov 2013
  • F-6EFEffective registration statement (depository shares)11 Feb 2013
  • SC 13D/AShamir Optical Industry Ltd.25 Jul 2011

Mentions in Filings

  • … e company in an advisory role until November 2025. Prior to Omnicell, Mr. Etta served as Senior Vice President and Chief Financial Officer of Essilor of America, Inc., an ophthalmic optics company and a subsidiary of <strong>EssilorLuxottica</strong> SA, from October 2019 to October 2022. Prior to that, Mr. Etta served as the Vice President and Chief Financial Officer of Johnson & Johnson Vision, a medtech business segment and a subsidiary of Johnson & Johnson, f …
    Trinzic, Inc.Essilor International /FI Unsponsored ADR·EX-99.1 - 10-12B/A - EXHIBIT 99.1·Q4 26·9 Nov
  • <strong>EssilorLuxottica</strong>, the global leader in the eyewear industry, partnered with the VTEX CX Platform to deploy a sophisticated suite of AI agents for its direct-to-consumer brand, E-lens, transforming its customer service into a highly proactive sales engine. The primary goal was to automate the complex, high-touch journey of purchasing prescription contact lenses online. By implementing intelligent agents, the company automated critical touchpoints, …
    VTEXEssilor International /FI Unsponsored ADR·6-K - Current report (foreign private issuer)·Q3 26·5 Nov
  • … e he oversaw the company’s global finance, information technology, investor relations strategies, from 2023 to 2025, and Senior Vice President and Chief Financial Officer for Essilor of America, Inc., a subsidiary of <strong>EssilorLuxottica</strong> SA, from 2019 through 2022. Before those roles, Mr. Etta served as the Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision from 2015 to 2019, and for the previous nine years, he held vari …
    U S PHYSICAL THERAPY INC /NVEssilor International /FI Unsponsored ADR·EX-99.2 - 8-K - Entry into a Material Definitive Agreement·Q3 26·14 Aug
  • … logy, consumer products and private equity sectors for more than 25 years. Prior to joining Omnicell, Mr. Etta served as Senior Vice President and Chief Financial Officer for Essilor of America, Inc., a subsidiary of <strong>EssilorLuxottica</strong> SA, from 2019 to 2022. Before that role, Mr. Etta served as the Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision from 2015 to 2019, and for the previous nine years, he held various sen …
    U S PHYSICAL THERAPY INC /NVEssilor International /FI Unsponsored ADR·8-K - Entry into a Material Definitive Agreement·Q3 26·14 Aug
  • … $500 million Tampines Campus more than doubles Applied’s advanced cleanroom capacity in Singapore and strengthens the company’s global manufacturing footprint. •Announced a long-term joint development agreement with <strong>EssilorLuxottica</strong> to accelerate the commercialization of next-generation intelligent optical systems for augmented reality and AI-powered smart eyewear. •Published our latest Impact Report highlighting how Applied is progressing towa …
    APPLIED MATERIALS INC /DEEssilor International /FI Unsponsored ADR·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·13 Aug
  • … 89 Eiffage SA, Class P 8,485 1,261,273 \*Ekinops SAS 20 55 Electricite de Strasbourg SA, Class B 76 19,710 Ω\*Elior Group SA 12,487 42,367 Elis SA 7,267 211,808 \*Emeis SA 4,670 75,668 <strong>EssilorLuxottica</strong> SA, Class B 2,377 729,292 Eurofins Scientific SE 7,058 572,143 ΩEuronext NV 3,369 472,537 Exosens SAS 1,297 83,167 FDJ UNITED 15,578 414,015 \*FIGEAC-AERO 784 10,026 Fnac Darty SA 2,008 …
    Dimensional ETF TrustEssilor International /FI Unsponsored ADR·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug

Key Stats

Trading

Px/Chg 1D$80.84 / +0.41%
Avg Volume131.15K
Beta0.86
Mkt Cap74.31B
FD Mkt Cap86.03B

Float

Shrs Out/Float919.18M / 294.01M
Short Float0.00%
Days to Cover1.00
Stock Repurchased$361.16M

Current Valuation

EV88.41B
EV/EBITDA0.00
EV/Sales0.00
P/B1.91
P/S0.00
FCF Yield3.22%
ROE5.72%
ROA3.48%
Current Ratio0.99

Dividend

Cash$2.35
Yield2.38%
Yield (TTM)2.38%

Estimates

P/E0.00
Est P/E0.00
Est EPS1.57
Est PEG0.00

Valuation

Metric5Yr AvgJun '22Jun '23Jun '24Jun '25Oct '26
PRICE-BASED RATIOS
Price / Earnings51.7745.4237.6942.4352.6780.67
Price / Sales4.063.323.313.824.695.17
Price / Book Value2.311.882.172.543.081.91
Price / Free Cash Flow28.2518.7125.2629.1737.0631.04
ENTERPRISE VALUE METRICS
Enterprise Value100,273.478,000.092,247.3106,875.0135,830.888,414.1
Enterprise Value / Sales4.643.943.774.215.126.16
Enterprise Value / EBITDA20.0616.8315.1217.2920.7230.35
Enterprise Value / EBIT40.2334.7128.9433.0639.3065.16

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue8.4%19,820.024,494.025,395.026,508.027,366.5
Gross Income7.8%12,284.015,593.016,048.016,806.016,573.0
EBITDA7.6%4,634.06,103.06,181.06,554.06,218.5
EBIT9.5%2,247.03,188.03,233.03,456.03,228.4
Net Income11.3%1,448.02,152.02,289.02,359.02,223.6
EPS (Diluted)10%1.632.422.542.572.39
BALANCE SHEET
Cash & ST Inv1.8%3,293.01,960.02,559.02,251.03,542.5
Total Assets1.8%59,415.060,561.060,523.064,264.063,867.8
Total Liabilities89.3%23,540.022,414.021,631.023,262.024,392.6
Total Shareholder Equity2.6%35,064.037,455.038,239.040,376.038,872.4
CASH FLOW
Net Operating Cash Flow2.8%4,545.04,783.04,861.04,874.05,082.2
Cap Ex9.2%-1,030.0-1,572.0-1,531.0-1,522.0-1,464.8
Free Cash Flow72%3,515.03,211.03,330.03,352.03,617.4

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)100.55
Basic Shares919.18
Market Cap92,423.9
Diluted Shares928.86
Fully Diluted Shares Outstanding928.86
Fully Diluted Market Cap93,396.5
+Consolidated Debt15,309.7
−In-the-Money Convertible Debt—
+Capital Leases3,905.8
+Operating Leases—
−Cash & Equivalents-1,930.2
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest710.7
+Pension Liabilities—
Enterprise Value106,514.0

Related companies

Bnp Paribas

BNPQY US

Zijin Mining Group Co., Ltd./ADR

ZIJMF US

Atlas Copco Ab

ATLPF US

Glencore plc/ADR

GLNCY US

Volvo AB Class A

VOLAF US

TKMS AG & Co KGaA

TKMCY US

Singapore Telecommunications Ltd

SGAPY US

Compass Group Plc

CMPGY US

Sumitomo Electric Industries, Ltd.

SMTOY US

Sandvik Ab /FI

SDVKY US

Heineken Nv /ADR/

HINKF US

Tesco Plc /FI

TSCDY US

ESLOY US​
Ask AI

Essilor International /FI Unsponsored ADR — Company Profile

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Exchange
UU
CEO
Francesco Milleri
Headquarters
Paris, I0, FR
IPO Date
Jan 30, 2008
Employees
203,791
Website
www.essilorluxottica.com

Key Metrics

Price
$80.84
Market Cap
$74.31B
Revenue (TTM)
$27.37B
Net Income (TTM)
$2.22B
EPS (TTM)
2.42
P/E (TTM)
0.00
P/B (TTM)
1.91
Dividend Yield
2.38%
ROE (TTM)
5.72%
ROA (TTM)
3.48%
Operating Margin
11.80%
Beta
0.86

Dividends

Last Dividend
$2.35
Last Yield
0.02%

Summary

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. The company specializes in the creation, production, and worldwide distribution of a diverse range of vision products, including ophthalmic lenses, eyewear frames, and sunglasses, catering to markets across North America, Europe, Latin America, Asia, Oceania, and Africa. Its extensive operations are divided into five key segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division is responsible for manufacturing and supplying premium and athletic eyewear to other businesses. Conversely, the Retail segment directly offers luxury and sports eyewear to consumers through its various sales channels. The Lenses and Optical Instruments segment provides a broad spectrum of lenses, such as Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (including the Gen 8 series), Eyezen lenses optimized for digital screen use, and Xperio polarized sun lenses, alongside corrective options from Nikon and Kodak. This segment also furnishes optical instruments, including lens edging and mounting equipment for opticians and laboratories, and optometry tools for a variety of professionals and institutions, while also developing online optical sales solutions. The Equipment segment focuses on delivering advanced digital surfacing and lens coating machinery to prescription laboratories, integrated optical chains, and lens manufacturers. Lastly, the Sunglasses and Readers segment encompasses a wide array of non-prescription sunglasses and reading glasses, available under numerous well-known proprietary brands like Foster Grant, Magnivision, and SolarShield, licensed brands such as Reebok, Steve Madden, and Disney, and regional labels including Bolon and Mujosh. To support its expansive business, EssilorLuxottica maintains a substantial network of 490 prescription laboratories and edging-mounting facilities globally. The company formally adopted the name EssilorLuxottica Société anonyme in October 2018, having previously been known as Essilor International Société Anonyme.

Website
www.essilorluxottica.com
Location
Paris, I0, FR
Phone33 1 49 77 42 16
Employees203,791
CEOFrancesco Milleri
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO DateJan 30, 2008

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(87)

Expand
  • F-6EFEffective registration statement (depository shares)25 Nov 2019
  • F-6 POSPost-effective amendment (depository shares)18 Oct 2018
  • F-6 POSPost-effective amendment (depository shares)9 Oct 2018
  • Form 425Business combination communication17 May 2017
  • Form 425Business combination communication29 Mar 2017
  • Form 425Business combination communication29 Mar 2017
  • Form 425Business combination communication23 Mar 2017
  • Form 425Business combination communication21 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication1 Feb 2017
  • Form 425Business combination communication24 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • Form 425Business combination communication17 Jan 2017
  • SC 13DCOSTA INC18 Nov 2013
  • Form 3ESSILOR INTERNATIONAL /FI18 Nov 2013
  • F-6EFEffective registration statement (depository shares)11 Feb 2013
  • SC 13D/AShamir Optical Industry Ltd.25 Jul 2011

Mentions in Filings

  • … e company in an advisory role until November 2025. Prior to Omnicell, Mr. Etta served as Senior Vice President and Chief Financial Officer of Essilor of America, Inc., an ophthalmic optics company and a subsidiary of <strong>EssilorLuxottica</strong> SA, from October 2019 to October 2022. Prior to that, Mr. Etta served as the Vice President and Chief Financial Officer of Johnson & Johnson Vision, a medtech business segment and a subsidiary of Johnson & Johnson, f …
    Trinzic, Inc.Essilor International /FI Unsponsored ADR·EX-99.1 - 10-12B/A - EXHIBIT 99.1·Q4 26·9 Nov
  • <strong>EssilorLuxottica</strong>, the global leader in the eyewear industry, partnered with the VTEX CX Platform to deploy a sophisticated suite of AI agents for its direct-to-consumer brand, E-lens, transforming its customer service into a highly proactive sales engine. The primary goal was to automate the complex, high-touch journey of purchasing prescription contact lenses online. By implementing intelligent agents, the company automated critical touchpoints, …
    VTEXEssilor International /FI Unsponsored ADR·6-K - Current report (foreign private issuer)·Q3 26·5 Nov
  • … e he oversaw the company’s global finance, information technology, investor relations strategies, from 2023 to 2025, and Senior Vice President and Chief Financial Officer for Essilor of America, Inc., a subsidiary of <strong>EssilorLuxottica</strong> SA, from 2019 through 2022. Before those roles, Mr. Etta served as the Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision from 2015 to 2019, and for the previous nine years, he held vari …
    U S PHYSICAL THERAPY INC /NVEssilor International /FI Unsponsored ADR·EX-99.2 - 8-K - Entry into a Material Definitive Agreement·Q3 26·14 Aug
  • … logy, consumer products and private equity sectors for more than 25 years. Prior to joining Omnicell, Mr. Etta served as Senior Vice President and Chief Financial Officer for Essilor of America, Inc., a subsidiary of <strong>EssilorLuxottica</strong> SA, from 2019 to 2022. Before that role, Mr. Etta served as the Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision from 2015 to 2019, and for the previous nine years, he held various sen …
    U S PHYSICAL THERAPY INC /NVEssilor International /FI Unsponsored ADR·8-K - Entry into a Material Definitive Agreement·Q3 26·14 Aug
  • … $500 million Tampines Campus more than doubles Applied’s advanced cleanroom capacity in Singapore and strengthens the company’s global manufacturing footprint. •Announced a long-term joint development agreement with <strong>EssilorLuxottica</strong> to accelerate the commercialization of next-generation intelligent optical systems for augmented reality and AI-powered smart eyewear. •Published our latest Impact Report highlighting how Applied is progressing towa …
    APPLIED MATERIALS INC /DEEssilor International /FI Unsponsored ADR·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·13 Aug
  • … 89 Eiffage SA, Class P 8,485 1,261,273 \*Ekinops SAS 20 55 Electricite de Strasbourg SA, Class B 76 19,710 Ω\*Elior Group SA 12,487 42,367 Elis SA 7,267 211,808 \*Emeis SA 4,670 75,668 <strong>EssilorLuxottica</strong> SA, Class B 2,377 729,292 Eurofins Scientific SE 7,058 572,143 ΩEuronext NV 3,369 472,537 Exosens SAS 1,297 83,167 FDJ UNITED 15,578 414,015 \*FIGEAC-AERO 784 10,026 Fnac Darty SA 2,008 …
    Dimensional ETF TrustEssilor International /FI Unsponsored ADR·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug

Key Stats

Trading

Px/Chg 1D$80.84 / +0.41%
Avg Volume131.15K
Beta0.86
Mkt Cap74.31B
FD Mkt Cap86.03B

Float

Shrs Out/Float919.18M / 294.01M
Short Float0.00%
Days to Cover1.00
Stock Repurchased$361.16M

Current Valuation

EV88.41B
EV/EBITDA0.00
EV/Sales0.00
P/B1.91
P/S0.00
FCF Yield3.22%
ROE5.72%
ROA3.48%
Current Ratio0.99

Dividend

Cash$2.35
Yield2.38%
Yield (TTM)2.38%

Estimates

P/E0.00
Est P/E0.00
Est EPS1.57
Est PEG0.00

Valuation

Metric5Yr AvgJun '22Jun '23Jun '24Jun '25Oct '26
PRICE-BASED RATIOS
Price / Earnings51.7745.4237.6942.4352.6780.67
Price / Sales4.063.323.313.824.695.17
Price / Book Value2.311.882.172.543.081.91
Price / Free Cash Flow28.2518.7125.2629.1737.0631.04
ENTERPRISE VALUE METRICS
Enterprise Value100,273.478,000.092,247.3106,875.0135,830.888,414.1
Enterprise Value / Sales4.643.943.774.215.126.16
Enterprise Value / EBITDA20.0616.8315.1217.2920.7230.35
Enterprise Value / EBIT40.2334.7128.9433.0639.3065.16

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue8.4%19,820.024,494.025,395.026,508.027,366.5
Gross Income7.8%12,284.015,593.016,048.016,806.016,573.0
EBITDA7.6%4,634.06,103.06,181.06,554.06,218.5
EBIT9.5%2,247.03,188.03,233.03,456.03,228.4
Net Income11.3%1,448.02,152.02,289.02,359.02,223.6
EPS (Diluted)10%1.632.422.542.572.39
BALANCE SHEET
Cash & ST Inv1.8%3,293.01,960.02,559.02,251.03,542.5
Total Assets1.8%59,415.060,561.060,523.064,264.063,867.8
Total Liabilities89.3%23,540.022,414.021,631.023,262.024,392.6
Total Shareholder Equity2.6%35,064.037,455.038,239.040,376.038,872.4
CASH FLOW
Net Operating Cash Flow2.8%4,545.04,783.04,861.04,874.05,082.2
Cap Ex9.2%-1,030.0-1,572.0-1,531.0-1,522.0-1,464.8
Free Cash Flow72%3,515.03,211.03,330.03,352.03,617.4

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)100.55
Basic Shares919.18
Market Cap92,423.9
Diluted Shares928.86
Fully Diluted Shares Outstanding928.86
Fully Diluted Market Cap93,396.5
+Consolidated Debt15,309.7
−In-the-Money Convertible Debt—
+Capital Leases3,905.8
+Operating Leases—
−Cash & Equivalents-1,930.2
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest710.7
+Pension Liabilities—
Enterprise Value106,514.0

Related companies

Bnp Paribas

BNPQY US

Zijin Mining Group Co., Ltd./ADR

ZIJMF US

Atlas Copco Ab

ATLPF US

Glencore plc/ADR

GLNCY US

Volvo AB Class A

VOLAF US

TKMS AG & Co KGaA

TKMCY US

Singapore Telecommunications Ltd

SGAPY US

Compass Group Plc

CMPGY US

Sumitomo Electric Industries, Ltd.

SMTOY US

Sandvik Ab /FI

SDVKY US

Heineken Nv /ADR/

HINKF US

Tesco Plc /FI

TSCDY US